

Winter 1-1-1996

Analysis of the effects of overexpression of metallothionein-I in transgenic mice on the reproductive toxicology of cadmium.

T Dalton
University of Kansas Medical Center

Kai Fu
University of Nebraska Medical Center, kfu@unmc.edu

G C Enders
University of Kansas Medical Center

R D Palmiter
University of Washington - Seattle Campus

G K Andrews
University of Kansas Medical Center

Tell us how you used this information in this [short survey](#).

Follow this and additional works at: https://digitalcommons.unmc.edu/com_pathmicro_articles



Part of the [Medical Microbiology Commons](#), and the [Pathology Commons](#)

Recommended Citation

Dalton, T; Fu, Kai; Enders, G C; Palmiter, R D; and Andrews, G K, "Analysis of the effects of overexpression of metallothionein-I in transgenic mice on the reproductive toxicology of cadmium." (1996). *Journal Articles: Pathology and Microbiology*. 29.

https://digitalcommons.unmc.edu/com_pathmicro_articles/29

This Article is brought to you for free and open access by the Pathology and Microbiology at DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Pathology and Microbiology by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Analysis of the Effects of Overexpression of Metallothionein-I in Transgenic Mice on the Reproductive Toxicology of Cadmium

Tim Dalton,¹ Kai Fu,¹ George C. Enders,² Richard D. Palmiter,³ and Glen K. Andrews¹

¹Department of Biochemistry and Molecular Biology and ²Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS 66160-7421 USA; ³Department of Biochemistry, Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195 USA

Exposure to low levels of cadmium reduces fertility. In male mice spermatogenesis is highly sensitive to cadmium, whereas in females the peri-implantation period of pregnancy is sensitive. To examine the potential roles of the cadmium-binding protein, metallothionein (MT), in the reproductive toxicology of cadmium, we examined a transgenic mouse strain that overexpresses metallothionein-I (MT-I). These mice had dramatically increased steady-state levels of MT-I mRNA and MT in the testes and in the female reproductive tract during the peri-implantation period of pregnancy, and this overexpression occurred in a cell-specific and temporally regulated manner similar to that of the endogenous *MT-I* gene. Transgenic and control males were injected with cadmium, and the histology of the testes was examined. An injection of 7.5 $\mu\text{mol Cd/kg}$ had no effect on histology of the testes in either transgenic or control mice. In contrast, an injection of 10 $\mu\text{mol Cd/kg}$ caused rapid changes in the histology of the testes and resulted in pronounced testicular necrosis in both control and transgenic mice. Female transgenic and control mice were mated and then injected with cadmium (30–45 $\mu\text{mol Cd/kg}$) on the day of blastocyst implantation (day 4). In both of these groups, injection of cadmium reduced pregnancy rate, and no dramatic protection was afforded by maternal and/or embryonic overexpression of MT. Thus, overexpression of MT-I does not significantly protect against either of these cadmium-induced effects on fertility. **Key words:** cadmium, metallothionein, peri-implantation, reproductive toxicology, transgenic mice, testes. *Environ Health Perspect* 104:68–76 (1996)

Cadmium is a widely distributed, toxic trace metal. Cadmium poisoning causes damage to major organ systems, and in humans this leads to Itai-Itai disease (1,2). This nonessential transition metal is also carcinogenic (3–5) and is deleterious to the reproductive process, causing retardation of growth, sterility, teratogenic, and embryotoxic effects (6–8). In rodents, spermatogenesis has long been known to be highly susceptible to cadmium. In sensitive strains of mice, the testes undergo necrosis after exposure to cadmium (9,10). Likewise, injection of pregnant female mice with a sublethal dose of cadmium on the day of blastocyst implantation (day 4) significantly reduces pregnancy rate by midgestation (11). Cadmium exerts embryotoxic effects on preimplantation embryos *in vitro* (12,13), and these effects are particularly dependent on the stage of embryonic development, with the blastocyst being the most sensitive to cadmium toxicity (11,14). However, cadmium also exerts toxic effects on the female reproductive tract and can delay the onset of implantation (11). After implantation, the deciduum, placenta, and visceral yolk sac may serve to protect the embryo by restricting the passage of cadmium from the mother, but exposure to cadmium during the organogenic period can induce limb bud and craniofacial defects (6,7). Mechanisms that may protect against the reproductive toxicity of cadmium are largely unknown.

Metallothioneins (MT) are a family of cysteine-rich cadmium-binding proteins (15) whose genes are transcriptionally activated by cadmium (16). Because MTs have been shown to protect against cadmium toxicity in cultured cells (17,18) and in mice (19–21) they are prime candidates for protecting against toxic effects of cadmium on reproductive processes.

Several strains of mice that overexpress MT have been created using a minimally mutated *MT-I* (*MT-I**) gene under the control of 1.8-kb of the mouse MT-I promoter and flanked by the MT-I/MT-II locus control regions (LCR) (22). In these mice, the *MT-I** transgene is expressed in a copy-number-dependent, integration-site-independent manner, and developmental expression appears to mimic the endogenous gene. We examined one of these transgenic mouse strains and reported that MT is overexpressed in most major organs (23). In this study we documented the level of expression and tissue-specific distribution of MT in reproductive organs (uterus and testes) of male and female transgenic and control mice from this strain and evaluated the role of MT in protection against cadmium-induced testicular damage and early pregnancy failure.

Methods

Animals. All experiments involving animals were conducted in accordance with

National Institutes of Health standards for the care and use of experimental animals. The transgenic mice used in these studies were derived from heterozygous males that carry 56 copies of minimally mutated *MT-I* (*MT-I**) gene on the B6/SJL F₁ background (22). These mice were outbred to CD-1 females (Charles River Breeding Laboratories, Raleigh, North Carolina), and the heterozygous male offspring were selected. These heterozygous males were bred with CD-1 females, and experiments were performed using the transgenic and non-transgenic (control) littermates from this breeding. We identified transgenic and control mice by DNA slot blot analysis. For experiments involving pregnant animals, virgin females of the indicated strain (48–68 days old) were mated with males of the indicated strain, and the morning a vaginal plug was detected was defined as day 1 of pregnancy.

Cadmium injection. CdCl₂ (Sigma Chemical Co., St. Louis, Missouri) was dissolved in acidified normal saline and administered in a single 100- μl subcutaneous injection. Dosages of cadmium ranged from 7.5 to 45 $\mu\text{mol/kg}$ body weight. To determine the effect of cadmium on pregnancy, we injected cadmium on the morning of day 4 and assessed pregnancy success on day 14 as described (11). The effect of cadmium on the testes was determined by histological examination 24 and 48 hr after cadmium injection.

MT determination. MT was determined by the cadmium-hemoglobin exchange assay as described (24). For convenience, tissue samples were frozen in liquid nitrogen and stored at -70°C before analysis.

Address correspondence to G. K. Andrews, Department of Biochemistry and Molecular Biology, BFR 2034, University of Kansas Medical Center, 39th and Rainbow Boulevard, Kansas City, KS 66160-7421 USA.

This work was supported in part by NIH grants (ES-04725, ES-05704, and CA-61262) to G.K. Andrews (CA-61268), R. D. Palmiter, and G. C. Enders (HD-26639). T. Dalton was supported by postdoctoral fellowships from the Kansas Health Foundation and the Marion-Merrel Dow Scientific Education Partnership. We are indebted to Jim Geiser for excellent technical assistance and to S. K. Dey for help in immunolocalization studies.

Received 2 August 1995; accepted 18 September 1995.

Isolation of RNA and Northern blot hybridization. Tissues were frozen in liquid nitrogen and stored at -70°C before RNA extraction. RNA was prepared by an initial guanidine thiocyanate (GTC)/phenol/chloroform extraction as described (25), followed by sodium dodecyl sulfate (SDS)/phenol/chloroform extractions (26,27). Poly A⁺ RNA was isolated as described by Aviv and Leder (28), using total RNA and oligo(dT) cellulose (Collaborative Biochemicals, Bedford, Massachusetts; 20 mg total RNA/0.5 g cellulose).

RNA was size fractionated by formaldehyde-agarose gel electrophoresis and Northern blotted to nylon membranes (29). Northern blots were prehybridized, hybridized with a mouse MT-I ³²P-labeled cRNA probe (specific activity = 2×10^9 dpm/ μg), and washed (26,29,30). Hybrids were detected by autoradiography at -70°C with intensifying screens. In all experiments, we stained duplicate gels with acridine orange to verify integrity and equal loading of RNA.

Competitive reverse transcriptase-PCR analysis of MT-I and MT-I* mRNAs. Competitive reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, under reaction conditions essentially as described (31), to differentiate between MT-I* and endogenous MT-I mRNAs. Oligonucleotide primers specific for MT-I were designed based on the sequence of the mouse MT-I cDNA that flanks the MT-I* mutation (32):

sense strand

5' CACCACGACTTCAACGTCCTG 3'

antisense strand

5' TCTTGCAGGCGCAGGAGCTG 3'

These primers correspond to nucleotides 3–23 in the 5' untranslated region (exon 1) and to nucleotides 604–623 (exon 2) of the mouse MT-I gene, respectively. Total RNA (25 μg) was reverse transcribed with recombinant mouse murine leukemia virus reverse transcriptase (Gibco-BRL, Gaithersburg, Maryland) using the antisense oligo as a primer. One-fourth of the RT reaction mixture was amplified by PCR for 20 cycles in a reaction containing 0.2 μM each unlabeled MT-I primer, 1×10^7 cpm of ³²P-5'-end labeled antisense MT-I primer ($5\text{--}10 \times 10^6$ dpm/pmol), and 1 unit of Taq polymerase (Perkin-Elmer Cetus, Norwalk, Connecticut). Cycle parameters were as follows: cycle 1: 94°C for 4 min, primer annealing at 55°C for 2 min and primer extension 72°C for 2 min; cycles 2–20: 94°C for 30 sec, 55°C for 2 min, and 72°C for 2 min. RT-PCR prod-

ucts were purified using magic PCR prep columns (Promega Biotech, Madison, Wisconsin) and 1×10^5 cpm was digested with excess restriction enzyme (*Bgl* II and/or *EcoRV*). *EcoRV* will cleave the MT-I* product, whereas *Bgl* II cleaves the endogenous MT-I gene product (22). Restriction fragments were separated by 12% nondenaturing polyacrylamide gel electrophoresis. After fixation in 10% acetic acid for 10 min, the gel was dried and exposed to Kodak XAR-5 film at -70°C for a few hours.

Solution hybridization. Oligonucleotide excess solution hybridization was used to quantitate MT-I mRNA levels as described (33). Total RNA or poly A⁺ RNA (0–30 μg) plus carrier *E. coli* rRNA (20–50 μg ; Boehringer Mannheim, Indianapolis, Indiana) were mixed and hybridized with 10 fmol of ³²P-end-labeled antisense oligonucleotide complementary to the 3' untranslated region of MT-I (34) as described previously (30,33). The oligonucleotide was end-labeled with T4 polynucleotide kinase according to the manufacturer's suggestions (New England Biolabs, Inc., Beverly, Massachusetts) and had a specific activity of $5\text{--}10 \times 10^6$ cpm/pmol. After hybridization, S1 nuclease resistant nucleic acids were precipitated with 20% trichloroacetic acid and collected on glass fiber filters (Whatman GF/C; Fisher Scientific, Pittsburgh, Pennsylvania) and the radioactivity was measured by liquid scintillation counting. Samples were in duplicate. Each set of hybridization reactions also included a standard curve generated using known amounts of sense-strand RNA which was transcribed *in vitro* from the MT-I cDNA clone (33).

MT antibodies. A rabbit polyclonal antiserum against a synthetic peptide corresponding to the amino-terminal 15 amino acids of mouse MT-I (NacMDPNASA STGGSATCamide) (32) was prepared commercially by Immuno-Dynamics (La Jolla, California). Fine epitope mapping of rat MT-II suggested that the acetylated amino-terminal pentapeptide is the primary antigenic determinant and that the acetate group on the amino-terminal methionine is important for antigenicity (35). Therefore, the peptide was acetylated on the amino-terminal methionine after synthesis and the C-terminal cysteine carboxyl group was converted to an amide. Cysteine residues corresponding to amino acids 5, 7, and 13 were substituted with alanine. For injection, this peptide was conjugated to keyhole limpet hemocyanin through the C-terminal cysteine sulfhydryl group.

Immunohistochemistry and histology. Immunolocalization of MT-I was per-

formed essentially as described (27,36–38). Briefly, uteri were excised, cleaned of fat, and either fixed intact in Bouin's solution or implantation sites were grossly dissected from interimplantation regions and then fixed in Bouin's. Testes were removed from mature males (>68 days old) after perfusion fixation with Bouin's and cut into small pieces which were further fixed in Bouin's. Fixed tissues were dehydrated and embedded for paraffin sections. Paraffin sections (7 μm) were incubated in 10% normal goat serum for 10 min before incubation with primary antibody (1:500 dilution) for 16–20 hr at 4°C . For uteri, we used a kit for the anti-rabbit primary antibody (Zymed Laboratories, San Francisco, California) for immunostaining. This kit used a biotinylated secondary antibody, a horseradish peroxidase-streptavidin conjugate, and a substrate chromogen mixture. After incubation in secondary antibody, we blocked endogenous peroxidase by incubation in 0.23% periodic acid in phosphate-buffered saline for 45 sec (39). For testis, we used a kit containing a biotinylated secondary antibody, an alkaline phosphatase-streptavidin conjugate, and an AP-red substrate chromogen mixture for immunostaining. After color development, sections were counterstained lightly with hematoxylin, mounted, and examined under bright field. Red deposits indicated sites of immunostaining. No specific staining was detected in control sections incubated without primary antibody or with nonimmune serum. Furthermore, in all cases specific staining was greatly reduced or eliminated in sections in which the primary antibody was neutralized with a 200-fold excess of MT peptide. For histological analysis of the testes, we used the same fixation, embedding, and sectioning procedures, and sections were stained with eosin.

Results

MT-I mRNA Levels

To determine whether MT transgenes are overexpressed in the testes and peri-implantation uterus of transgenic animals, total RNA was prepared from these tissues and MT-I mRNA levels were quantitated by solution hybridization. This assay employed an oligonucleotide that detected both endogenous MT-I and transgene-derived MT-I* transcripts. MT-I mRNA levels were elevated 8.3-fold in total RNA from the testes of transgenic compared with control nontransgenic littermates (Fig. 1A). In the uterus, at sites of embryo implantation, MT-I mRNA levels were elevated 20.2-fold on day 6 and 8.6-fold on day 8 compared to levels in control mice. During this period, days 6–8, there is massive growth of the

deciduum, which surrounds the embryo and actively expresses the entire *MT* gene locus (33,40). Northern analysis showed that *MT-I* mRNA levels in transgenic mice are highest in the implantation sites/deciduum compared to the interimplantation regions of the uterus (Fig. 1B). Solution




Figure 1. *MT-I* mRNA levels in the testes and peri-implantation uterus of transgenic and control mice. (A) Total *MT-I* (*MT-I* plus *MT-I**) mRNA was quantitated by solution hybridization using an excess of an oligonucleotide complementary to *MT-I* mRNA. Sense-strand *MT-I* RNA was used to generate a standard curve for quantitation of *MT-I* mRNA levels. Data are expressed as means \pm SDs, $n = 6$. For each tissue, the transgenic mRNA level was significantly different from control ($p < 0.001$, Student's *t*-test). Testis RNA was obtained from four to six animals for each group. Sites of blastocyst implantation site were dissected and pooled from the uteri of pregnant mice ($n = 4$) on days 6 and 8 of pregnancy. Implantation sites on day 8 were dissected free of the myometrium. (B) The top panel is a Northern blot of *MT-I* mRNA in total RNA (2 μ g) from implantation sites (IS) or interimplantation sites (IIS) isolated from the uteri of pregnant mice on days 6 or 8 of gestation/pregnancy. RNAs from control (-) and transgenic (+) mice are compared. The bottom panel is an acridine orange-stained duplicate gel which demonstrates equal loading of 28s and 18s ribosomal RNAs.

hybridization and Northern analysis both show a developmental increase in *MT-I* mRNA levels in the deciduum of control (11.2-fold) and transgenic (4.8-fold) mice




Figure 2. Competitive reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the relative abundance of *MT-I* and *MT-I** mRNAs in the testes and peri-implantation uterus of transgenic and control mice. Total RNA from control (-/-) and transgenic (+/-) tissues was subjected to competitive RT-PCR using oligonucleotides that flank the *MT-I** mutation and that are complementary to *MT-I* and *MT-I** mRNAs. The *MT-I* mRNA RT-PCR product is cut by *Bg/II* (Bg), whereas the *MT-I** mRNA RT-PCR product is cut by *EcoRV* (RV). RT-PCR products were radiolabeled by inclusion of a 32 P-labeled primer in the PCR reaction. Restriction products were separated by 12% nondenaturing polyacrylamide gel electrophoresis and visualized by autoradiography and quantitated by radioanalysis of the gel.

between days 6 and 8, as previously shown in CD-1 mice (40).

We used competitive RT-PCR to evaluate the relative expression of *MT-I** transgenes and the endogenous *MT-I* gene in the testes and peri-implantation uterus of transgenic mice. Transcripts from the *MT-I** gene contains an *EcoRV* site derived by modification of the *Bg/II* site at +62 in the 5'-untranslated region (22). RT-PCR across this region using oligonucleotides complementary to both transcripts, followed by cleavage of the RT-PCR product with *EcoRV* and/or *Bg/II*, differentiates products derived from the *MT-I** transgene and the endogenous *MT-I* gene, respectively. Results of this analysis revealed that RT-PCR products from *MT-I** mRNA represent the majority (>90%) of the *MT-I* mRNA in the testes and peri-implantation uterus from transgenic mice (Fig. 2). As expected, *EcoRV* does not cut RT-PCR products from control mice. These RT-PCR products do not represent PCR of DNA because they are dependent on reverse transcription, and PCR of genomic sequences would yield a larger product due to the inclusion of intronic sequences. The nature of the larger PCR product that was not cut with *EcoRV* or *Bg/II* was not investigated, but probably represents heteroduplexes (22).

Determination of *MT* Levels in Tissues

To determine whether *MT* accumulates to higher levels in the testes and peri-implantation uterus of transgenic mice, *MT* was quantitated in heat-stable tissue extracts using the cadmium-hemoglobin exchange assay (24). Cadmium-binding was increased significantly in all the major organs examined from transgenic mice compared with those from control mice (Fig. 3), as expected from our previous studies (23). In the transgenic testes, *MT* levels were 5.2-fold higher than in control mice, and in uterine implantation sites *MT* levels were 8.7-fold higher on day 6 and 2.6-fold higher on day 8 than levels in control mice. As predicted by increases in *MT-I* mRNA between day 6 and day 8, deciduum *MT* levels correspondingly increased during this period in both transgenic and control mice (Fig. 3). In general, the increases in *MT-I* mRNA in the transgenic compared to control mice (Fig. 1) are accompanied by increases in heat-stable cadmium-binding activity in these tissues.

Immunohistochemical Localization of *MT*

Expression of the mouse *MT* genes is cell specific in the peri-implantation uterus (33,40) and in the testes (41). To deter-




Figure 3. Determination of steady-state levels of MT in tissues of transgenic and control female and male mice. MT was determined by the cadmium–hemoglobin exchange assay (24) in heat-stable extracts prepared from the tissues. Uterus, deciduum, liver, kidney, and pancreas were obtained from female transgenic and control mice. Day-4 uterus represents MT in the whole uterus, whereas day-6 uterus represents MT in the implantation sites, and day-8 deciduum represents MT in deciduum dissected free of the myometrium. Testes were isolated from mature breeding males. Data represent the means \pm SDs of at least three independent assays of tissues pooled from three animals each. For each tissue the transgenic MT level was significantly different from control ($p < 0.001$, Student's *t*-test).

mine whether the *MT-I** gene is also expressed in a cell-specific manner in these transgenic mice, MT-I was immunolocalized in the day-4 uterus, day-6 and day-8 deciduum, and in the testis (Fig. 4) using an anti-MT-peptide antisera. Our studies of CD-1 mice demonstrated that abundant MT-I mRNA is found in uterine luminal and glandular epithelium on day 4 and in the secondary decidual zone on days 6–8 (40). MT-I immunoreactivity was also localized only to these locations in uterine sections from control mice (Fig. 4A). Specificity of the antisera was confirmed using nonimmune sera (not shown) and by antibody neutralization (Fig. 4) before immunostaining. In uterine sections from transgenic mice, MT immunostaining was also restricted to the same cell types as in nontransgenic mice (Fig. 4B), but the immunostaining was notably more intense.

Sections from the testes of control mice displayed only weak MT-I immunoreactivity confined to one or two Leydig cells per field of view (Fig. 5A). Using preabsorbed antibody eliminated this staining (Fig. 5B). In transgenic animals, MT immunoreactivity was also confined to Leydig cells (Fig. 5D, E), but the immunostaining was intense and many Leydig cells were immunopositive for MT. Interestingly, elevated MT-I mRNA levels in the testes

reflect accumulation of high levels of these transcripts in the spermatogenic cells (41). MT apparently does not accumulate in germ cells, but does so at low levels in Leydig cells in control mice and is elevated in these cells in transgenic mice. The above results establish that the *MT-I** genes are overexpressed, and MT accumulates to higher levels in the proper cell types in the testes and female reproductive tract in this transgenic line of mice.


Effects of Cadmium Injected on the Day of Blastocyst Implantation

Previous studies have documented a marked susceptibility of the blastocyst to acute cadmium exposure both *in vivo* and *in vitro* (11–13). We reported that subcutaneous injection of a sublethal dose of cadmium (38 $\mu\text{mol/kg}$) on day 4 of pregnancy resulted in loss of pregnancy, accompanied by a loss in viability of blastocysts flushed from the uterus on day 5 (11). However, maternal effects of cadmium were also noted in those studies and were likely to play a role in the loss of pregnancy. To determine if cell-specific overexpression of MT would protect against cadmium-induced pregnancy failure, transgenic and control mice were given a single subcutaneous injection of cadmium on the morning of day 4 of pregnancy, before blastocyst

implantation, and pregnancy was assessed by gross dissection of the uterus on day 14 (Table 1). Mice used in these experiments were divided into three groups based on expression of MT: group 1 mice had normal maternal and embryonic MT gene expression and consisted of nontransgenic females (CD-1 or control) mated with CD-1 males. Group 2 mice had normal maternal MT gene expression but overexpression of embryonic MT and consisted of CD-1 females mated with heterozygous transgenic males (50% transgenic embryos). Group 3 mice had maternal and embryonic overexpression of MT and consisted of heterozygous transgenic females mated with CD-1 males (50% transgenic embryos).

In untreated mice, 90–100% of the females that had a vaginal plug on day 1 were found to be pregnant at mid-gestation (day 14), and there were no differences among transgenic, control, and CD-1 females in the number of implantation sites per uterus or the percentage of embryos that had died and were resorbed by day 14 (Table 1). To examine the effects of cadmium on pregnancy, three doses (30, 40, and 45 $\mu\text{mol Cd/kg}$ body weight) were administered on day 4 to mice in each of these groups. Each of these doses of cadmium reduced the pregnancy rate similarly in all three groups of mice. An injection of 30 $\mu\text{mol Cd/kg}$ slightly reduced the pregnancy rate (to 80–90%) in each group, but had no effect on the number of implantation sites per uterus, the day-14 fetal weight, or embryo resorption rate. In contrast, an injection of 40 $\mu\text{mol Cd/kg}$ resulted in a sharp decline in pregnancy rate (46–62%) in all three groups (Table 1). In each experiment the pregnancy rate was consistently higher in mice with maternal and embryonic overexpression of MT (group 3) than in the other groups of mice. However, there were no remarkable differences between the three groups of mice with regard to the effects of cadmium on pregnancy rate.

Under these experimental conditions, 40 $\mu\text{mol Cd/kg}$ was at the low end of the steep dose–response curve for lethality for each of these groups of mice (Table 1). In experiment 1, 40 $\mu\text{mol Cd/kg}$ did not kill any of the mice examined. In contrast, in experiment 2, 1 of 24 transgenic mice died, and 4 of 18 control mice died. An injection of 45 $\mu\text{mol Cd/kg}$ resulted in significant lethality in all groups, but was below the LD_{50} . Surprisingly, there were no remarkable differences in the dose–response curves for cadmium lethality among these groups of mice. It was noted that cadmium injection on day 4 resulted in an all-or-none effect on pregnancy, which is consistent




with maternal cadmium toxicity governing pregnancy rate. In all three groups, mice that escaped the effects of cadmium and were pregnant on day 14 had a normal number of implantation sites, and there was no increase in resorption rate (Table 1). Thus, embryonic overexpression of MT afforded no selective advantage.

Effects of Cadmium on Spermatogenesis

The rodent testis is highly sensitive to the toxic effects of cadmium (9,10,42), and necrosis occurs after the administration of cadmium at levels well below those that cause liver or kidney damage. Transgenic or control male mice were injected with a single subcutaneous dose of cadmium at 7.5 or 10 $\mu\text{mol/kg}$, and 24 hr or 48 hr later the testes were recovered and examined histologically (Fig. 6). The histology of the testis 48 hr after an injection of 7.5 $\mu\text{mol Cd/kg}$ was unchanged in both transgenic and control mice (Fig. 6A,B). However, 24 hr after an injection of 10 $\mu\text{mol Cd/kg}$, alterations in the seminiferous epithelium were apparent (Fig. 6C,D) and by 48 hr extensive testicular necrosis, edema, and sloughing of the seminiferous epithelium had occurred in both transgenic and control mice (Fig. 6E,F). These results demonstrate that overexpression of *MT* affords no apparent protection against cadmium-induced testicular necrosis.

Figure 4. Immunohistochemical localization of MT in the peri-implantation uterus from transgenic and control mice. Control (A) and (B) transgenic mice were mated, and uteri were removed on day 4, or implantation sites were dissected from uteri on days 6 and 8. See Methods for details. Dark deposits show MT immunostaining. Preabsorption of the antisera with MT peptide eliminated immunostaining (A, bottom right; B, top right). E, epithelium (luminal and glandular); M, myometrium; PDZ, primary decidua zone; SDZ, secondary decidua zone. (A) (top left) day-4 uterus, 28 \times ; (top right) day-4 uterus, 69 \times ; (middle left) day-6 implantation site 28 \times ; (middle right) day-6 implantation site, 69 \times ; (bottom left) day 8 implantation site, 21 \times ; (bottom right) day-6 preabsorbed antisera control, 28 \times . (B) (top left) day-4 uterus, and (top right) preabsorbed antisera control, both 28 \times ; (bottom left) day 6 implantation site, 28 \times ; (bottom right) day-6 implantation site, 69 \times ; (directly below) day-8 implantation site, 25 \times .






Figure 5. Immunohistochemical localization of MT in the testis of transgenic and control mice. Testes were recovered from (A,B) control (-/-) and (C-E) transgenic (+/-) males. See Methods for details. Dark deposits show MT immunostaining. Preabsorption of the antisera with peptide eliminated immunostaining (B,C). SE, seminiferous epithelium; L, Leydig cell. Panels (A,B) 62 \times , (C,D) 69 \times , (E) 276 \times . Arrows indicate MT immunostaining in Leydig cells. In panel A, control testes immunostaining was confined to one cell in this field of view, and the staining was faint, making it difficult to reproduce photographically.

Table 1. Effects of cadmium injection on day 4 of pregnancy in transgenic, control, and CD-1 mice^a

	Parents		Cd (μ mol/kg)	n (total female)	Lethality (%) ^b	Pregnancy rate (%) ^c	Embryos per female ^d	Embryos resorbed (%)	Embryo weight (g)
	Female	Male							
Experiment 1	CD-1	CD-1	30	10	0	80	10.9 \pm 1.9	3.7	0.13
		Transgenic	40	14	0	50	11.2 \pm 2.2	6.9	0.12
	Transgenic	CD-1	30	9	0	89	12.0 \pm 1.8	6.2	0.12
		Transgenic	40	13	0	46	11.8 \pm 1.2	4.4	0.13
Experiment 2	CD-1	Transgenic	40	8	0	62	10.2 \pm 1.8	7.8	
			40	13	0	54	13.1 \pm 2.2		
		45	13	23	50	14.4 \pm 1.3			
	Transgenic	CD-1	40	24	4	60	10.3 \pm 4.5		
			45	8	38	57	10.2 \pm 3.0		
		Control	40	18	22	57	12.0 \pm 1.4		
Untreated	CD-1	CD-1	45	10	20	50	10.8 \pm 1.9		
			0	4	—	100	13.2 \pm 1.5	3.8	
	Transgenic	CD-1	0	20	—	90	10.5 \pm 2.4	6.0	
			0	11	—	100	12.4 \pm 1.8	5.3	

^aFemale and male mice of the indicated lines were mated, and on day 4 (day 1 = vaginal plug) females were administered the indicated dosage of CdCl₂ in a single 100 μ l subcutaneous injection. On day 14 animals were sacrificed and pregnancy status was evaluated after gross dissection.

^bDetermined as the number of animals that died between day 4 and day 14 of pregnancy, inclusive, divided by the total number of animals injected with cadmium in that group.

^cDetermined as the number of day 14 pregnant animals divided by the total number of mice alive on day 14.

^dData represent the means \pm SDs.

Discussion

The transgenic mice used in this study have stable integration of 56 copies of an *MT-I** transgene with 1.8 kb of the *MT-I* promoter and flanked by 10 kb of DNA 5' of the *MT-II* gene and 7 kb of DNA 3' of the *MT-I* gene (22). This construct is expressed in a manner that resembles the endogenous *MT-I* gene (22,23,43). We extended those studies to include the peri-implantation


uterus where the temporal as well as spatial patterns of expression of the endogenous *MT-I* gene (40) and the *MT-I** transgene were indistinguishable. This suggests that the *MT-I** transgene-LCR construct contains all of the information necessary to direct developmental expression of the *MT-I* gene in the uterine epithelium and the deciduum. Although the DNA regions involved in this developmental regulation are unknown, we recently reported that the

entire *MT* gene locus is activated in the mouse deciduum (33). This is the only known tissue in which each of the four mouse *MT* genes are activated, which suggests that the chromatin domain structure of the *MT* locus may be particularly important in regulating expression in these cells.

This transgenic mouse strain provided a useful tool to examine the functional significance of MT in cadmium toxicity. Specifically, effects of MT overexpression on cadmium toxicity during early pregnancy and on the testes were examined. Surprisingly, these indicators did not reveal a remarkable protective effect of overexpression of MT, although a slight protection from loss of pregnancy was noted. Our previous studies of these transgenic mice revealed that they are more resistant to cadmium-induced hepatotoxicity and acute lethality compared with control mice (19), but the dose-response curves for cadmium-induced lethality revealed only a subtle increase (1.2-fold) in cadmium dosage resulted in equivalent lethality between the transgenic and control mice. Such subtle differences in dose response to cadmium were not revealed in the limited dose-response experiments here.

By comparison, cultured cells that overexpress MT, after transfection with an MT expression vector, can resist 12- to 15-fold higher concentrations of cadmium in the culture medium than control cells (18), and cultured cells selected for cadmium resistance that overexpress MT can resist up to 60-fold higher concentrations of cadmium (44). Interestingly, primary hepatocytes from this transgenic strain that overexpresses MT are about 7-fold more resistant to cadmium toxicity *in vitro*. Thus, large differences between transgenic and control mice in their resistance to cadmium toxicity were predicted based on studies of cultured cells, but studies of these transgenic mice demonstrate that within the physiological context of the animal, overexpression of MT affords little protection from cadmium toxicity.

In contrast, studies of mice in which the *MT-I* and *MT-II* genes have been disrupted suggest a significant increase in sensitivity to cadmium-induced hepatotoxicity and lethality (20,21). Although no detailed dose-response curves for cadmium toxicity have been reported, studies of these mice reveal clear increases in cadmium toxicity. Control mice can tolerate 14 daily injections of 10 μ mol Cd/kg, whereas the knockout mice succumb after 2-4 days, depending on sex (21). Embryonic fibroblasts from these knockout mice are also 2- to 3-fold more sensitive to cadmium *in vitro* than are control fibroblasts (45).



Therefore, MT can serve a protective function against cadmium *in vivo*, but overexpression of MT in a proper cell-specific manner does not significantly augment that protective function.

It is perhaps surprising that overexpression of MT at its normal sites of synthesis in the mouse did not effectively protect early pregnancy or spermatogenesis from cadmium toxicity by scavenging cadmium from the serum. After acute exposure to cadmium, the liver can sequester up to 60% of the cadmium challenge (46,47), and hepatotoxicity is closely associated with cadmium-induced mortality (48,49). MT in the transgenic liver was significantly elevated, and the liver is considered responsible for cadmium detoxification. Despite these considerations, no protection was afforded these reproductive processes, and low levels of cadmium caused testicular necrosis in both the control and transgenic mice.

In the testes of nontransgenic animals, MT immunostaining using an antipeptide antisera was confined to a few Leydig cells. In transgenic animals, MT immunostaining was exclusively in Leydig cells, but was much more intense. These results suggest that the Leydig cell is the only cell that accumulates immunodetectable MT in the mouse testes and that levels of MT are normally low in the control testes. Previous studies have yielded conflicting results regarding the immunolocalization of MT in the rodent testes. MT has been shown to be immunolocalized to Leydig cells in the mouse testis (50), but in the rat testes MT immunostaining in Sertoli cells and interstitial cells has been reported (51), as has localization in spermatogenic cells, but not in interstitial cells (52). It is interesting that MT immunoreactivity was not present in mouse germ cells, as pachytene spermatocytes and round spermatids express high levels of MT-I mRNA and can synthesize MT (41). Pachytene spermatocytes and round spermatids isolated from these transgenic mice also contained high levels of MT-I mRNA, and the vast majority of it was derived from the *MT-I** transgene (data not shown). The lack of MT immunostaining in these germ cells is con-

Figure 6. Effects of cadmium injection on histology of the testes from transgenic and control mice. (A,C,E) Control (-/-) and (B,D,F) transgenic male littermates were given a single injection of 7.5 $\mu\text{mol Cd/kg}$ (A,B) or 10 $\mu\text{mol Cd/kg}$ (C-F), and the testes were recovered 24 hr (C,D) or 48 hr (A,B,E,F) after the injection. Testes were fixed in Bouin's solution, and paraffin sections were prepared and stained with hematoxylin and eosin. SE, seminiferous epithelium; L, Leydig cell; SSE, sloughing seminiferous epithelium. (A-F) 39 \times .

sistent with the suggestion that MT accumulation is controlled primarily by post-transcriptional mechanisms in male germ cells (41).

Some inbred strains of mice show remarkable resistance to testicular necrosis produced by lethal doses of cadmium (53,54), and this is attributed to the autosomal recessive *cdm* gene (55). Although it has been proposed that in the rat, testicular susceptibility to cadmium is the result of the low expression of *MT* genes (56,57), the studies reported here suggest that the *cdm* gene is a far more important genetic determinant for testicular sensitivity to cadmium than is the level of testicular MT. Overexpression of MT in the testes was not sufficient to protect from cadmium-induced testicular damage. Leydig cells are not required for the effects of cadmium on the testes (58), but elevation of MT in Leydig cells present in the interstitium of the testes might be expected to protect the germ cells because the interstitium is the major site of cadmium accumulation in the testes (59,60). Collectively, these studies establish that MT in the interstitium is of limited use in preventing testicular injury after cadmium exposure.

Our earlier studies indicated that pregnancy failure after cadmium exposure on day 4 may have resulted from a direct embryotoxic effect on the blastocyst (11). However, the results obtained here, using a larger number of mice, strongly suggest that effects of cadmium on the mother play the key role in the maintenance of pregnancy. Although transgenic blastocysts from these mice display marked elevation in MT (approximately 10-fold) compared to control blastocysts and more resistant to Cd toxicity *in vitro* (43), studies reported here establish that transgenic embryos have no selective advantage *in vivo* after maternal exposure to cadmium under these experimental conditions. Pregnancy failure after cadmium exposure on day 4 may result from effects on the uterus; for example, on uterine receptivity for implantation. We previously reported that cadmium can cause a delay in the initiation of implantation (localized sites of increased uterine vascular permeability) in mice (11). After implantation, cadmium has restricted access to the embryo, perhaps due to the high levels of MT expressed in the deciduum and visceral yolk sac (6,7,61). Despite increased expression of MT in these tissues, the transgenic mice were not significantly protected from cadmium toxicity during the peri-implantation period.

Studies of cadmium toxicity in these transgenic mice that overexpress MT are consistent with the likelihood that cadmi-

um exerts its lethal effects, in part, on cells that do not overexpress MT. It has been suggested that hepatic endothelial cells are a target of cadmium toxicity and that this may account for strain differences in susceptibility (62). Cadmium-induced testicular damage has also been suggested to result from injury to the vasculature, which leads to ischemia and death of seminiferous epithelium (63–65). In that regard, the process of blastocyst implantation involves highly localized increases in vascular permeability at the sites of embryo implantation. Immunolocalization of MT in these transgenic mice did not suggest enhanced accumulation in endothelial cells of the testes or uterus. The ovary and placenta are also susceptible to cadmium toxicity (6), but dosages of cadmium that disrupt the testes had little effect on the establishment and maintenance of pregnancy.

REFERENCES

- Emmerson BT. "Ouch-ouch" disease: the osteomalacia of cadmium nephropathy. *Ann Intern Med* 73:854–855 (1970).
- Friberg L, Elinder C-G, Kjellstrom T, Nordberg GF. Cadmium and health: a toxicological and epidemiological appraisal. Boca Raton, FL: CRC Press, 1986.
- Sunderman FW. Carcinogenicity and mutagenicity of some metals and their compounds. In: *Environmental carcinogens: selected methods of analysis* (O'Neill IK, Schuller P, Fishbein L, eds). Lyon: International Agency for Research on Cancer, 1986;17–43.
- Poirier LA, Kasprzak KS, Hoover KL, Wenk ML. Effects of calcium and magnesium acetates on the carcinogenicity of cadmium chloride in Wistar rats. *Cancer Res* 43:4575–4581 (1983).
- Waalkes MP, Rehm S, Riggs CW, Bare RM, Devor DE, Poirier LA, Wenk ML, Henneman JR. Cadmium carcinogenesis in male Wistar [CrI:(WI)BR] rats: dose-response analysis of effects of zinc on tumor induction in the prostate, in the testes, and at the injection site. *Cancer Res* 49:4282–4288 (1989).
- Barlow SM, Sullivan FM. Cadmium and its compounds. In: *Reproductive hazards of industrial chemicals* (Barlow SM, Sullivan FM, eds). London: Academic Press, 1982;136–155.
- Dencker L, Danielsson B, Khayat A, Lindgren A. Disposition of metals in the embryo and fetus. In: *Reproductive and developmental toxicity of metals* (Clarkson TW, Nordberg GF, Sager PR, eds). New York: Plenum Publishers, 1983;607–632.
- Vallee BL, Ulmer DD. Biochemical effects of mercury, cadmium, and lead. *Annu Rev Biochem* 41:91–128 (1972).
- Parizek J. The destructive effect of cadmium ion on testicular tissue and its prevention by zinc. *J Endocrinol* 15:56–63 (1957).
- Gunn SA, Clark-Gould T, Anderson WA. Zinc protection against cadmium injury to rat testis. *Arch Pathol* 71:274–281 (1961).
- De SK, Paria BC, Dey SK, Andrews GK. Stage-specific effects of cadmium on preimplantation embryo development and implantation in the mouse. *Toxicology* 80:13–25 (1993).
- Schmid BP, Hall JL, Goulding E, Fabro S, Dixon R. In vitro exposure of male and female mice gametes to cadmium chloride during the fertilization process, and its effects on pregnancy outcome. *Toxicol Appl Pharmacol* 69:326–332 (1983).
- Yu HS, Tam PP, Chan ST. Effects of cadmium on preimplantation mouse embryos in vitro with special reference to their implantation capacity and subsequent development. *Teratology* 32:347–353 (1985).
- Andrews GK, Huet-Hudson YM, Paria BC, McMaster MT, De SK, Dey SK. Metallothionein gene expression and metal regulation during preimplantation mouse embryo development (MT mRNA during early development). *Dev Biol* 145:13–27 (1991).
- Vallee BL. Metallobiochemistry: Part B. Metallothionein and related molecules. Introduction to metallothionein. *Methods Enzymol* 205:3–7 (1991).
- Palmiter RD. Molecular biology of metallothionein gene expression. *Exper Suppl* 52:63–80 (1987).
- Beach LR, Palmiter RD. Amplification of the metallothionein-I gene in cadmium-resistant mouse cells. *Proc Natl Acad Sci USA* 78:2110–2114 (1981).
- Morton KA, Jones BJ, Sohn MH, Schaefer AE, Phelps RC, Datz FL, Lynch RE. Uptake of cadmium is diminished in transfected mouse NIH/3T3 cells enriched for metallothionein. *J Biol Chem* 267:2880–2883 (1992).
- Liu Y, Liu J, Iszard MB, Andrews GK, Palmiter RD, Klaassen CD. Transgenic mice that overexpress metallothionein-I are protected from cadmium lethality and hepatotoxicity. *Toxicol Appl Pharmacol* (in press).
- Michalska AE, Choo KHA. Targeting and germ-line transmission of a null mutation at the metallothionein I and II loci in mouse. *Proc Natl Acad Sci USA* 90:8088–8092 (1993).
- Masters BA, Kelly EJ, Quaife CJ, Brinster RL, Palmiter RD. Targeted disruption of metallothionein I and II genes increases sensitivity to cadmium. *Proc Natl Acad Sci USA* 91:584–588 (1994).
- Palmiter RD, Sandgren EP, Koeller DM, Brinster RL. Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice. *Mol Cell Biol* 13:5266–5275 (1993).
- Iszard MB, Liu JL, Liu Y, Dalton TD, Andrews GK, Palmiter RD, Klaassen CD. Characterization of metallothionein-I transgenic mice. *Toxicol Appl Pharmacol* 13:305–312 (1995).
- Eaton DL, Chierian MG. Determination of metallothionein in tissues by cadmium-hemoglobin affinity assay. *Methods Enzymol* 205:83–88 (1991).
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156–159 (1987).
- Andrews GK, Huet YM, Lehman LD, Dey SK. Metallothionein gene regulation in the preimplantation rabbit blastocyst. *Development* 100:463–469 (1987).
- Dalton TD, Kover K, Dey SK, Andrews GK. Analysis of the expression of growth factor, interleukin-1 and lactoferrin genes and the distribution of inflammatory leukocytes in the preimplantation mouse oviduct. *Biol Reprod* 51:597–606 (1994).
- Aviv H, Leder P. Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. *Proc Natl Acad Sci USA* 69:1408–1412 (1972).
- Dalton TD, Palmiter RD, Andrews GK. Transcriptional induction of the mouse metallothionein-I gene in hydrogen peroxide-treated Hepa cells involves a composite major late transcription factor/antioxidant response element and metal response promoter elements. *Nucleic Acids Res* 22:5016–5023 (1994).
- De SK, McMaster MT, Andrews GK. Endotoxin induction of murine metallothionein gene expression. *J Biol Chem* 265:15267–15274 (1990).
- Paria BC, Das SK, Andrews GK, Dey SK. Expression of the epidermal growth factor receptor gene is regulated in mouse blastocysts during delayed implantation. *Proc Natl Acad Sci USA* 90:55–59 (1993).
- Durnam DM, Perrin F, Gannon F, Palmiter RD. Isolation and characterization of the mouse metallothionein-I gene. *Proc Natl Acad Sci USA* 77:6511–6515 (1980).
- Liang L, Lee DK, Sobieski RJ, Dalton T, Andrews GK. Activation of the complete metallothionein gene locus in the maternal deciduum. *Mol Reprod Dev* (in press).
- Glanville N, Durnam DM, Palmiter RD. Structure of mouse metallothionein-I gene and its mRNA. *Nature* 292:267–269 (1981).
- Kikuchi Y, Irie M, Ikebuchi H, Sawada J, Terao T, Nakayama S, Iguchi S, Okada Y. Antigenic determinants on rat metallothionein: fine epitope mapping for a murine monoclonal antibody and rabbit polyclonal antiserum. *J Biochem (Tokyo)* 107:650–654 (1990).
- Hsu SM, Raine L, Fanger H. The use of anti-avidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. *Am J Clin Pathol* 75:816–821 (1981).
- Kapur S, Tamada H, Dey SK, Andrews GK. Expression of insulin-like growth factor-I (IGF-I) and its receptor in the peri-implantation mouse uterus, and cell-specific regulation of IGF-I gene expression by estradiol and progesterone. *Biol Reprod* 46:208–219 (1992).
- Tamada H, McMaster MT, Flanders KC, Andrews GK, Dey SK. Cell type-specific expression of transforming growth factor- β 1 in the mouse uterus during the periimplantation period. *Mol Endocrinol* 4:965–972 (1990).
- Kelly J, Whelan CA, Weir DG, Feighery C. Removal of endogenous peroxidase activity from cryostat sections for immunoperoxidase visualisation of monoclonal antibodies. *J Immunol Methods* 96:127–132 (1987).
- De SK, McMaster MT, Dey SK, Andrews GK. Cell-specific metallothionein gene expression in mouse decidua and placenta. *Development* 107:611–621 (1989).
- De SK, Enders GC, Andrews GK. High levels of metallothionein messenger RNAs in male germ cells of the adult mouse. *Mol Endocrinol* 5:628–636 (1991).
- Gunn SA, Gould TC, Anderson WA. Selectivity of organ response to cadmium injury and various protective measures. *J Pathol Bacteriol* 96:89–96 (1968).
- Lee DK, Fu K, Liang L, Dalton T, Palmiter RD, Andrews GK. Transgenic mouse blasto-

- cysts that over-express metallothionein-I resist cadmium toxicity in vitro. *Mol Reprod Dev* (in press).
44. Palmiter RD. Constitutive expression of metallothionein-III (MT-III), but not MT-I, inhibits growth when cells become zinc deficient. *Toxicol Appl Pharmacol* (in press).
 45. Lazo JS, Kondo Y, Dellapiazza D, Michalska AE, Choo KHA, Pitt BR. Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. *J Biol Chem* 270:5506-5510 (1995).
 46. Cain K, Skilleter DN. Selective uptake of cadmium by the parenchymal cells of liver. *Biochem J* 188:285-288 (1980).
 47. Frazier JM, Puglese J. Dose dependence of cadmium kinetics in the rat liver following intravenous injection. *Toxicol Appl Pharmacol* 43:461-474 (1978).
 48. Meek ES. Cellular changes induced by cadmium in the mouse testis and liver. *Br J Exp Pathol* 40:503-506 (1959).
 49. Dudley RE, Svoboda DJ, Klaassen C. Acute exposure to cadmium causes severe liver injury in rats. *Toxicol Appl Pharmacol* 65:302-313 (1982).
 50. Nolan CV, Shaikh ZA. An evaluation of tissue metallothionein and genetic resistance to cadmium toxicity in mice. *Toxicol Appl Pharmacol* 85:135-144 (1986).
 51. Danielson KG, Ohi S, Huang PC. Immunochemical detection of metallothionein in specific epithelial cells of rat organs. *Proc Natl Acad Sci USA* 79:2301-2304 (1982).
 52. Nishimura H, Nishimura N, Tohyama C. Localization of metallothionein in the genital organs of the male rat. *J Histochem Cytochem* 38:927-933 (1990).
 53. Gunn SA, Gould TC, Anderson WA. Strain differences in susceptibility of mice and rats to cadmium-induced testicular damage. *J Reprod Fertil* 10:273-275 (1965).
 54. Chiquoine AD, Suntzeff V. Sensitivity of mammals to cadmium necrosis of the testis. *J Reprod Fertil* 10:455-457 (1965).
 55. Taylor BA, Heiniger HJ, Meier H. Genetic analysis of resistance to cadmium-induced testicular damage in mice. *Proc Soc Exp Biol Med* 143:629-633 (1973).
 56. Deagen JT, Whanger PD. Properties of cadmium-binding proteins in rat testes. Characteristics unlike metallothionein. *Biochem J* 231:279-283 (1985).
 57. Waalkes MP, Perantoni A, Bhawe MR, Rehm S. Strain dependence in mice of resistance and susceptibility to the testicular effects of cadmium: assessment of the role of testicular cadmium-binding proteins. *Toxicol Appl Pharmacol* 93:47-61 (1988).
 58. Bergh ARJ. The acute vascular effects of cadmium in the testis do not require the presence of Leydig cells. *Toxicology* 63:183-186 (1990).
 59. Johnson AD, Sigman MB. Early actions of cadmium in the rat and domestic fowl testis. IV. Autoradiographic location of ^{115m}Cd. *J Reprod Fertil* 24:115-117 (1971).
 60. Berlin M, Ullberg S. The fate of ¹⁰⁹Cd in the mouse. An autoradiographic study after a single intravenous injection of ¹⁰⁹CdCl₂. *Arch Environ Health* 7:686-693 (1963).
 61. De SK, Dey SK, Andrews GK. Cadmium teratogenicity and its relationship with metallothionein gene expression in midgestation mouse embryos. *Toxicology* 64:89-104 (1990).
 62. Liu J, Kershaw WC, Liu YP, Klaassen CD. Cadmium-induced hepatic endothelial cell injury in inbred strains of mice. *Toxicology* 75:51-62 (1992).
 63. Gunn SA, Clark-Gould T, Anderson WAD. The selective injurious response to testicular and epididymal blood vessels to cadmium and its prevention by zinc. *Am J Pathol* 42:685-702 (1963).
 64. Chiquoine AD. Observations on the early events of cadmium necrosis of the testis. *Anat Rec* 149:23-35 (1964).
 65. Nolan CV, Shaikh ZA. The vascular endothelium as a target tissue in acute cadmium toxicity. *Life Sci* 39:1403-1409 (1986).

Second Annual Genetic Screening & Diagnosis of Human Diseases

March 7-8, 1996
San Francisco, California

The sequencing effort of the Human Genome Project is complementing and simplifying efforts of positional cloning, leading to a dramatic rise in the number of genes identified for inherited disorders, as well as genes and mutations that may predispose an individual to greater risk of other more common diseases. The technology for detection of such genes and mutations, as well as some of the very powerful implications of screening the genetic makeup of individuals, will be covered. Reports on efforts related to the identification and detection of genes and mutations for specific diseases, including cancers, Alzheimer's disease, and cardiovascular disorders, will be featured on the second day.

Advance Registration Deadline: 1/19/96

Poster Deadline: 2/2/96

For information, contact:

Mary Chitty, Cambridge Healthtech Institute
1037 Chestnut Street, Newton Upper Falls, MA 02164
(617) 630-1300 FAX: (617) 630-1325